01:59 AM EDT, 10/22/2026 (MT Newswires) -- Molecular Partners (MOLN.SW) selected MP0730 as its lead targeted alpha radiotherapeutic candidate against the tumor-associated antigen CD70, with a first-in-human study expected to begin in mid-2027. The clinical-stage biotech company said Thursday that preclinical data showed strong, sustained tumor uptake relative to healthy tissue, including the kidney, liver, and blood, in tumor-bearing mice. CD70 is overexpressed in clear cell renal cell carcinoma and other cancers. MP0730 is the third program in the company's targeted alpha radiotherapeutics pipeline.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.